NCT06381843View on ClinicalTrials.gov

A Clinical Study to Evaluate the Safety and Immunogenicity of the Recombinant COVID-19 Vaccine (Sf9 Cell) as a Booster

NACompletedINTERVENTIONAL
Enrollment

120

Participants

Timeline

Start Date

August 2, 2022

Primary Completion Date

March 29, 2023

Study Completion Date

December 30, 2023

Conditions
COVID-19SARS-CoV-2 Infection
Interventions
BIOLOGICAL

Recombinant COVID-19 Vaccine (Sf9 Cell)

1dose, Intramuscular Injection

BIOLOGICAL

COVID-19 Vaccine (Vero Cell), Inactivated

1dose, Intramuscular Injection

Trial Locations (1)

Unknown

West China Hospital of Sichuan University, Chengdu

All Listed Sponsors
collaborator

West China Hospital

OTHER

lead

WestVac Biopharma Co., Ltd.

INDUSTRY